Novavax Covid vaccine to be made by Serum Institute, shows 90% efficacy
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Novavax Covid vaccine to be made by Serum Institute, shows 90% efficacy

Coronavirus chronicle

TBS Report
14 June, 2021, 05:45 pm
Last modified: 15 June, 2021, 05:47 pm

Related News

  • Indian vaccine giant Serum plans African plant in global expansion
  • Omicron-specific booster shot possible: SII CEO Adar Poonawalla
  • Serum Institute to resume supply of Covishield to Covax: Reports
  • Novavax Covid-19 vaccine gets first authorization; expects more within weeks, CEO says
  • India rules out reducing gap between Covishield doses

Novavax Covid vaccine to be made by Serum Institute, shows 90% efficacy

The jab "demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall," the company said in a statement

TBS Report
14 June, 2021, 05:45 pm
Last modified: 15 June, 2021, 05:47 pm
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

Novavax's Covid-19 jab is more than 90 percent effective, including against coronavirus variants, the vaccine maker said Monday after a large-scale US study.

The jab "demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall," the company said in a statement, adding "the study enrolled 29,960 participants across 119 sites in the US and Mexico to evaluate efficacy, safety and immunogenicity," reports the NDTV citing the Agence France-Presse.

The Maryland-headquartered company said it intended to apply for regulatory approval by the third quarter of 2021.

After that, it said, it would be on course to make 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year.

"Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional Covid-19 vaccines," said Stanley C. Erck, Novavax's president and chief executive.

"Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."

While some rich countries have made progress on vaccinating their populations, there remain concerns that many poorer countries are being left out of the global inoculation drive.

Vaccination rates in the world's poorest nations are far behind the Group of Seven industrialized powers and other wealthy states -- in terms of doses administered so far, the imbalance between the G7 and the planet's low-income countries, as defined by the World Bank, is 73 to one.

Unlike some rival jabs, Novavax's vaccine -- formally known as NVX-CoV2373 -- does not have to be stored at ultra-low temperatures.

The company said it was "stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution."

In theory at least, this means the shots should be more easily transported and administered in countries with less well developed health infrastructures.

Top News

Novavax Covid-19 Vaccine / Serum Institute of India (SII)

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A Regio regional passenger train operated by Deutsche Bahn AG travels on a bridge in Berlin. Photographer: Krisztian Bocsi/Bloomberg
    Why Germany is offering a summer of cheap trains
  • Patients opting to delay crucial treatment amid rising costs
    Patients opting to delay crucial treatment amid rising costs
  • Bankers unhappy with uniform exchange rate
    Bankers unhappy with uniform exchange rate

MOST VIEWED

  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Shanghai to lift 'unreasonable' curbs on firms, Beijing eases restrictions
  • Photo: Collected
    US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings

Related News

  • Indian vaccine giant Serum plans African plant in global expansion
  • Omicron-specific booster shot possible: SII CEO Adar Poonawalla
  • Serum Institute to resume supply of Covishield to Covax: Reports
  • Novavax Covid-19 vaccine gets first authorization; expects more within weeks, CEO says
  • India rules out reducing gap between Covishield doses

Features

Central bankers’ refusal to embark into ‘hard helicopter money’ experiment have been a good idea. Photo: Reuters

Venice has a 400-year-old Covid monetary lesson

1h | Panorama
Aiman R Khan. Illustration: TBS

Why ‘marry your rapist’ court orders are not always what they seem

4h | Thoughts
Photo: Collected

Top 3 The Ordinary products that give extraordinary results

6h | Mode
Photo: Courtesy

KVN Beauty: Channel your inner Bangalee baddie

6h | Mode

More Videos from TBS

Paper industry worth thousands of crores in Bogura

Paper industry worth thousands of crores in Bogura

55m | Videos
Photo: TBS

Tips to help you become a successful lawyer

7h | Videos
Photo: TBS

Harassment over 'indecent clothing': Women gather at Narsingdi railway station to protest, show solidarity

7h | Videos
People bid adieu to Abdul Gaffar Chowdhury

People bid adieu to Abdul Gaffar Chowdhury

7h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab